Updated

Updated · CNBC · Aug 27

FDA Approves Gilead's $4,595 Bixlenvo HIV Pill for 5% Unable to Use One-Tablet Options

Updated

Updated · CNBC · Aug 27

FDA Approves Gilead's $4,595 Bixlenvo HIV Pill for 5% Unable to Use One-Tablet Options

Q: What hidden danger lingers for months in the bodies of patients who suddenly stop taking Gilead's new HIV pill?

The main hidden danger is lenacapavir’s long pharmacokinetic “tail.” Because Bixlenvo contains lenacapavir, drug levels can linger in the body for months after someone stops the pill, with sub-therapeutic concentrations potentially persisting for roughly 106 to 235 days. That matters because those low, fading levels may not fully suppress HIV but can still pressure the virus to mutate. Experts warn this creates a window in which capsid resistance could emerge, potentially reducing the future usefulness of lenacapavir and related capsid-inhibitor treatment strategies. In practice, the risk is not that the drug suddenly becomes toxic after stopping. The concern is virologic: if a patient discontinues Bixlenvo without quickly switching to another fully suppressive HIV regimen, the residual lenacapavir exposure may give the virus an opportunity to rebound and select for resistance. That is why the approval and supporting clinical context stress careful switching and treatment planning. Patients should not stop Bixlenvo abruptly without medical guidance; they need prompt “bridging” to an alternative effective regimen to avoid that prolonged resistance-selection window.

3 articles · Updated · CNBC · Aug 27

Bixlenvo won FDA approval as the first single-tablet regimen for adults with HIV whose virus is suppressed but who cannot use existing one-pill options.
The once-daily pill combines bictegravir with lenacapavir to simplify care for patients on complex regimens, including those with drug resistance, side effects or drug interactions.
Phase 3 data showed viral suppression remained comparable to prior regimens through 48 weeks, with no new safety concerns; common side effects were headache, nausea and diarrhea.
Gilead said the eligible population represents 5% or more of people living with HIV in the U.S., and set a list price of $4,595 for a 30-day supply before discounts or rebates.
The approval also advances Gilead's broader lenacapavir strategy, which spans daily pills, weekly oral regimens and long-acting injections aimed at expanding individualized HIV treatment choices.